Our top pick for
Beginners
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.
How to buy Adaptive Biotechnologies Corporation stock | $48.29
Own Adaptive Biotechnologies Corporation stock in just a few minutes.
Adaptive Biotechnologies Corporation is a biotechnology business based in the US. Adaptive Biotechnologies Corporation shares (ADPT) are listed on the NYSE and all prices are listed in US Dollars. Adaptive Biotechnologies Corporation employs 453 staff and has a trailing 12-month revenue of around USD$92.2 million.
How to buy shares in Adaptive Biotechnologies Corporation
- Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
- Search for Adaptive Biotechnologies Corporation Find the stock by name or ticker symbol: ADPT. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Adaptive Biotechnologies Corporation reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of USD$48.29, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Adaptive Biotechnologies Corporation, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Adaptive Biotechnologies Corporation. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
Adaptive Biotechnologies Corporation share price
Use our graph to track the performance of ADPT stocks over time.Adaptive Biotechnologies Corporation shares at a glance
Information last updated 2020-09-25.
| Latest market close | USD$48.29 |
|---|---|
| 52-week range | USD$15.19 - USD$49 |
| 50-day moving average | USD$41.5583 |
| 200-day moving average | USD$36.9942 |
| Wall St. target price | USD$51.8 |
| PE ratio | 38.681 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | USD$-4.344 |
Compare trading platforms
Compare special offers, low fees and a wide range of types of investments among top trading platforms.The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Adaptive Biotechnologies Corporation stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Adaptive Biotechnologies Corporation price performance over time
Historical closes compared with the close of $48.29 from 2020-09-25
| 1 week (2020-09-22) | 0.46% |
|---|---|
| 1 month (2020-08-28) | 18.33% |
| 3 months (2020-06-29) | 4.84% |
| 6 months (2020-03-27) | 90.27% |
| 1 year (2019-09-27) | 59.32% |
|---|---|
| 2 years (2018-09-25) | N/A |
| 3 years (2017-09-25) | N/A |
| 5 years (2015-09-25) | N/A |
Is Adaptive Biotechnologies Corporation under- or over-valued?
Valuing Adaptive Biotechnologies Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Adaptive Biotechnologies Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Adaptive Biotechnologies Corporation's P/E ratio
Adaptive Biotechnologies Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 39x. In other words, Adaptive Biotechnologies Corporation shares trade at around 39x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Adaptive Biotechnologies Corporation financials
| Revenue TTM | USD$92.2 million |
|---|---|
| Gross profit TTM | USD$-7,908,000 |
| Return on assets TTM | -9.77% |
| Return on equity TTM | -24.57% |
| Profit margin | -107.96% |
| Book value | $4.133 |
| Market capitalisation | USD$6.2 billion |
TTM: trailing 12 months
Shorting Adaptive Biotechnologies Corporation shares
There are currently 2.8 million Adaptive Biotechnologies Corporation shares held short by investors – that's known as Adaptive Biotechnologies Corporation's "short interest". This figure is 0.8% up from 2.8 million last month.
There are a few different ways that this level of interest in shorting Adaptive Biotechnologies Corporation shares can be evaluated.
Adaptive Biotechnologies Corporation's "short interest ratio" (SIR)
Adaptive Biotechnologies Corporation's "short interest ratio" (SIR) is the quantity of Adaptive Biotechnologies Corporation shares currently shorted divided by the average quantity of Adaptive Biotechnologies Corporation shares traded daily (recently around 684916.50246305). Adaptive Biotechnologies Corporation's SIR currently stands at 4.06. In other words for every 100,000 Adaptive Biotechnologies Corporation shares traded daily on the market, roughly 4060 shares are currently held short.
However Adaptive Biotechnologies Corporation's short interest can also be evaluated against the total number of Adaptive Biotechnologies Corporation shares, or, against the total number of tradable Adaptive Biotechnologies Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Adaptive Biotechnologies Corporation's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Adaptive Biotechnologies Corporation shares in existence, roughly 20 shares are currently held short) or 0.0381% of the tradable shares (for every 100,000 tradable Adaptive Biotechnologies Corporation shares, roughly 38 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Adaptive Biotechnologies Corporation.
Find out more about how you can short Adaptive Biotechnologies Corporation stock.
Adaptive Biotechnologies Corporation share dividends
We're not expecting Adaptive Biotechnologies Corporation to pay a dividend over the next 12 months.
Adaptive Biotechnologies Corporation overview
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test; and Amgen to develop a therapeutic to prevent or treat COVID-19. It serves the life sciences research, clinical diagnostics, and drug discovery customers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was founded in 2009 and is headquartered in Seattle, Washington.
Frequently asked questions
Ask an Expert